Роль липопротеида(а) в развитии атеросклеротического поражения периферических и сонных артерий

Липопротеид(а) [Лп(а)] состоит из частицы, подобной липопротеиду низкой плотности (ЛНП), в которой апобелок В100 ковалентно связан с апобелком(а) с помощью одной дисульфидной связи. Лп(а) синтезируется в печени, и его концентрация в плазме крови составляет от 0 до 400 мг/дл. Повышенный уровень Лп(а) является независимым фактором риска развития сердечно-сосудистых заболеваний и ишемической болезни сердца. Данные о значении гиперлипопротеидемии (а) в развитии атеросклероза периферических артерий противоречивы. Обзор посвящен Лп(а), его связи с атеросклерозом различных сосудистых бассейнов, а также современным возможностям коррекции гиперлипопротеидемии(а).

липопротеид (а), периферический атеросклероз, атеросклероз сонных артерий, атеросклероз артерий нижних конечностей, lipoprotein (a), peripheral artery disease, carotid atherosclerosis, atherosclerosis of lower limbs arteries

1. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-382.

2. Tsimikas S. The re-emergence of lipoprotein(a) in a broader clinical arena. Prog Cardiovasc Dis 2016; 59 (2): 135-144.

3. Schmidt K., Noureen A., Kronenberg F., Utermann G. Structure, function, and genetics of lipoprotein (a). J. Lipid Res 2016; 57 (8): 1339-1359.

4. Kronenberg F., Utermann G. Lipoprotein(a): Resurrected by genetics. J. Intern Med 2013; 273 (1): 6-30.

5. Kraft H. G., Lingenhel A., Köchl S. et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996; 16 (6): 713-719.

6. Scanu A. M. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscler Rep 2003; 5 (2): 106-113.

7. Erqou S., Thompson A., Di Angelantonio E. et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J. Am Coll Cardiol 2010; 55 (19): 2160-2167.

8. Kronenberg F. Human genetics and the causal role oflipoprotein(a) for various diseases. Cardiovasc Drugs Ther 2016; 30 (1): 87-100.

9. Kostner K. M., Kostner G. M. Lipoprotein(a): A historical appraisal. J. Lipid Res 2017; 58 (1): 1-14.

10. Bucci M., Tana C., Giamberardino M. A., Cipollone F. Lp(a) and cardiovascular risk: Investigating the hidden side of the moon. Nutr Metab Cardiovasc Dis 2016; 26 (11): 980-986.

11. Marcovina S. M., Koschinsky M. L. Evaluation of lipoprotein (a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003; 14 (4): 361-366.

12. Hancock M. A., Boffa M. B., Marcovina S. M. et al. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J. Biol Chem 2003; 278 (26): 23260-23269.

13. Poon M., Zhang X., Dunsky K. G. et al. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997; 96 (8): 2514-2519.

14. Buechler C., Ullrich H., Aslanidis C. et al. Lipoprotein(a) down-regulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes. Biochim Biophys Acta 2003; 1642 (1-2): 25-31.

15. Boffa M. B., Marcovina S. M., Koschinsky M. L. Lipoprotein(a) as an emerging risk factor for atherothrombosis. In: Davidson M. H., Toth P. P., Maki K. C., Gotto Jr A. M. Therapeutic lipidology. Humana Press 2007; 241-266.

16. Tsimikas S., Brilakis E. S., Miller E. R. et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl J. Med 2005; 353 (1): 46-57.

17. Scipione C. A., Sayegh S. E., Romagnuolo R. et al. Mechanistic insights into Lp(a) - induced IL-8 expression: A role for oxidized phospholipid modification of apo(a). J. Lipid Res 2015; 56 (12): 2273-2285.

18. Wiesner P., Tafelmeier M., Chittka D. et al. MCP-1 binds to oxidized LDL and is carried by lipoprotein (a) in human plasma. J. Lipid Res 2013; 54 (7): 1877-1883.

19. O'Brien K. D., Reichenbach D. D., Marcovina S. M. et al. Apolipoproteins B.,(a), and E. accumulate in the morphologically early lesion of “degenerative" valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996; 16 (4): 523-532.

20. Alonso R., Andres E., Mata N. et al. Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J. Am Coll Cardiol 2014; 63 (19): 1982-1989.

21. Nordestgaard B. G., Chapman M.J., Ray K. et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31 (23): 2844-2853.

22. Erqou S., Kaptoge S., Perry P. L. et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302 (4): 412-423.

23. Guan W., Cao J., Steffen B. T. et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35 (4): 996-1001.

24. Laschkolnig A., Kollerits B., Lamina C. et al. Lipoprotein(a) concentrations, apolipoprotein(a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res 2014; 103 (1): 28-36.

25. Бритарева В. В., Афанасьева О. И., Добровольский А. Б. и др. Липопротеид(а) и изоформы апо(а) у больных с перемежающейся хромотой. Тер архив 2002; 74 (12): 49-52

26. Dieplinger B., Lingenhel A., Baumgartner N. et al. Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem 2007; 53 (7): 1298-1305.

27. Панченко Е. П., Добровольский А. Б., Перова Н. В., и др. Липидтранспортная система крови и фибринолиз у больных с различной протяженностью атеросклеротического поражения. Кардиология 1995; 12: 72-77

28. Hakim N. A., Hafizan M. T., Baizurah M. H., Zainal A. A. Serum lipoprotein(a) levels in patients with atherosclerotic peripheral vascular disease in Hospital Kuala Lumpur. Asian J. Surg 2008; 31 (1): 11-15.

29. Molgaard J., Klausen I. C., Lassvik С. et al. Significant association between low-molecular-weight apo(a) isoforms and intermittent claudication. Arterioscler Thromb 1992; 12 (8): 895-901.

30. Sutton-Tyrrell K., Evans R. W., Meilahn E., Alcorn H. G. Lipo-protein(a) and peripheral atherosclerosis in older adults. Atherosclerosis 1996; 122 (1): 11-19.

31. Price J. F., Lee A.J., Rumley A. et al. Lipoprotein(a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. Atherosclerosis 2001; 157 (1): 241-249.

32. Smolders B., Lemmens R., Thijs V. Lipoprotein(a) and stroke: a meta-analysis of observational studies. Stroke 2007; 38 (6): 1959-1966.

33. Unal E., Mungan S., Bilen S. et al. The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. Int J. Neurosci 2013; 123 (8): 532-536.

34. Bos S., Duvekot M. H., Touw-Blommesteijn A. C. et al. Lipo-protein(a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia. Atherosclerosis 2015; 242 (1): 226-229.

35. Nave A. H., Lange K. S., Leonards C. O. et al. Lipoprotein(a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis 2015; 242 (2): 496-503.

36. Kim B. S., Jung H. S., Bang O. Y. et al. Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke. Atherosclerosis 2010; 212 (2): 682-688

37. van Buuren F., Sommer J. A., Kottmann T. et al. Extracardiac manifestation of elevated lipoprotein(a) levels-cumulative incidence of peripheral arterial disease and stenosis of the carotid artery. Clin Res Cardiol Suppl 2015; 10: 39-45

38. Nasr N., Ruidavets J. B., Farghali A. et al. Lipoprotein(a) and carotid atherosclerosis in young patients with stroke. Stroke 2011; 42 (12): 3616-3618.

39. Kim S.J., Song P., Park J. H. et al. Biomarkers of asymptomatic carotid stenosis in patients undergoing coronary artery bypass grafting. Stroke 2011; 42 (3): 734-739.

40. Boden-Albala B., Kargman D. E., Lin I. F. et al. Increased stroke risk and lipoprotein(a) in a multiethnic community: the Northern Manhattan Stroke Study. Cerebrovasc Dis 2010; 30 (3): 237-243.

41. Beheshtian A., Shitole S. G., Segal A. Z. et al. Lipoprotein(a) level, apolipoprotein(a) size, and risk of unexplained ischemic stroke in young and middle-aged adults. Atherosclerosis 2016; 253: 47-53.

42. Lange K. S., Nave A. H., Liman T. G. et al. Lipoprotein(a) levels and recurrent vascular events after first ischemic stroke. Stroke 2017; 48(1): 36-42.

43. McCarthy M. Niacin fails to reduce vascular events in large randomised trial. BMJ 2014; 349: g4774.

44. Nicholls S.J., Ruotolo G., Brewer H. B. et al. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J. Clin Lipidol 2016; 10 (3): 519-527.

45. Thomas G. S., Cromwell W. C., Ali S. et al. Mipomersen, an apolipoprotein B. synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J. Am Coll Cardiol 2013; 62 (23): 2178-2184.

46. Desai N. R., Kohli P., Giugliano R. P. et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE) -thrombolysis in myocardial infarction (TIMI) 57 trial. Circulation 2013; 128 (9): 962-969.

47. Gaudet D., Watts G. F., Robinson J. G. et al. Effect of alirocumab on lipoprotein(a) over >1.5 years (from the phase 3 ODYSSEY program). AmJ Cardiol 2017; 119 (1): 40-46.

48. Graham M.J., Viney N., Crooke R. M., Tsimikas S. Antisense inhibition of apolipoprotein(a) to lower plasma lipoprotein(a) levels in humans. J. Lipid Res 2016; 57 (3): 340-351.

49. Tsimikas S., Viney N.J., Hughes S. G. et al. Antisense therapy targeting apolipoprotein(a): a randomized, double-blind, placebocontrolled phase 1 study. Lancet 2015; 386: 1472-1483.

50. Сафарова М. С., Афанасьева О. И. Применение афереза липопротеидов при атеросклерозе и его осложнениях. Атеросклероз и дислипидемии 2014; 2 (15): 5-16

51. Pokrovsky S. N., Afanasieva O. I., Ezhov M. V. Lipoprotein(a) apheresis. Curr Opin Lipidol 2016; 27 (4): 351-358.

52. Jaeger B. R., Richter Y., Nagel D. et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6 (3): 229-239.

53. Leebmann J., Roeseler E., Julius U. et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a) - hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128 (24): 2567-2576.

54. Safarova M. S., Ezhov M. V., Afanasieva O. I. et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013; 14 (1): 93-99.

55. Ezhov M. V., Safarova M. S., Afanasieva O. I. et al. Specific lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels. Atheroscler Suppl 2015; 18: 163-169.